Abbott Laboratories  

(Public, NYSE:ABT)   Watch this stock  
Find more results for ABT
+0.24 (0.41%)
Jan 19 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 58.96 - 59.68
52 week 39.25 - 59.68
Open 59.23
Vol / Avg. 7.36M/6.41M
Mkt cap 103.24B
P/E 48.90
Div/yield 0.28/1.89
EPS 1.21
Shares 1.74B
Beta 1.55
Inst. own 75%
Jan 24, 2018
Q4 2017 Abbott Laboratories Earnings Release - 9:30AM EST - Add to calendar
Jan 24, 2018
Q4 2017 Abbott Laboratories Earnings Call - 9:00AM EST - Add to calendar
Jan 8, 2018
Abbott Laboratories at JPMorgan Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 8.21% 5.10%
Operating margin 11.86% 15.27%
EBITD margin - 21.92%
Return on average assets 3.14% 2.26%
Return on average equity 7.07% 5.09%
Employees 75,000 -
CDP Score - A-


100 Abbott Park Rd
ABBOTT PARK, IL 60064-3500
United States - Map
+1-847-9376100 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Officers and directors

Miles D. White Chairman of the Board, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Brian B. Yoor Chief Financial Officer, Senior Vice President - Finance
Age: 47
Bio & Compensation  - Reuters
Michael T. Rousseau President - Cardiovascular and Neuromodulation
Age: 61
Bio & Compensation  - Reuters
Hubert L. Allen Executive Vice President, General Counsel, Secretary
Age: 51
Bio & Compensation  - Reuters
Stephen R. Fussell Executive Vice President - Human Resources
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Brian J. Blaser Executive Vice President - Diagnostics Products
Age: 52
Bio & Compensation  - Reuters
John M. Capek Ph.D. Executive Vice President - Ventures
Age: 55
Bio & Compensation  - Reuters
Robert B. Ford Executive Vice President - Medical Devices
Age: 43
Bio & Compensation  - Reuters
Heather L. Mason Executive Vice President - Nutritional Products
Age: 56
Bio & Compensation  - Reuters
Roger M Bird Senior Vice President - U.S. Nutrition
Age: 60
Bio & Compensation  - Reuters